MX362514B - Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. - Google Patents

Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.

Info

Publication number
MX362514B
MX362514B MX2015002605A MX2015002605A MX362514B MX 362514 B MX362514 B MX 362514B MX 2015002605 A MX2015002605 A MX 2015002605A MX 2015002605 A MX2015002605 A MX 2015002605A MX 362514 B MX362514 B MX 362514B
Authority
MX
Mexico
Prior art keywords
folate receptor
detection
diagnostic assays
kits
folri
Prior art date
Application number
MX2015002605A
Other languages
English (en)
Other versions
MX2015002605A (es
Inventor
N Carrigan Christina
e testa Nathan
Ab Olga
Tavares Daniel
B Wolf Beni
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX2015002605A publication Critical patent/MX2015002605A/es
Publication of MX362514B publication Critical patent/MX362514B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Abstract

La presente invención se refiere a anticuerpos que se unen al receptor 1 de folato humano y ensayos de diagnóstico para terapias basadas en el receptor 1 de folato. Se para monitorear la terapia. La presente invención proporciona métodos para la detección de FOLR1 en una muestra y puede usarse, por ejemplo, para estratificar pacientes. Por lo tanto, en una modalidad, la invención proporciona un método para tratar a un paciente que padece una enfermedad mediada por el receptor 1 de folato que comprende: (a) medir el nivel de expresión del receptor 1 de folato (FOLR1) diseminado o FOLR1 en una célula tumoral circulante (CTC) en una muestra tomada de un paciente.
MX2015002605A 2012-08-31 2013-08-30 Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. MX362514B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695791P 2012-08-31 2012-08-31
US201361756254P 2013-01-24 2013-01-24
PCT/US2013/057682 WO2014036495A2 (en) 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1

Publications (2)

Publication Number Publication Date
MX2015002605A MX2015002605A (es) 2015-06-10
MX362514B true MX362514B (es) 2019-01-22

Family

ID=50184673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002605A MX362514B (es) 2012-08-31 2013-08-30 Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.

Country Status (27)

Country Link
US (6) US9200073B2 (es)
EP (2) EP3712175A1 (es)
JP (6) JP6293147B2 (es)
KR (4) KR20200079565A (es)
CN (2) CN110294805B (es)
AU (4) AU2013308497B2 (es)
BR (1) BR112015004229B1 (es)
CA (2) CA2883222C (es)
CY (1) CY1122907T1 (es)
DK (1) DK2890717T3 (es)
ES (1) ES2788151T3 (es)
HK (1) HK1210188A1 (es)
HR (1) HRP20200482T1 (es)
HU (1) HUE049693T2 (es)
IL (4) IL299620A (es)
LT (1) LT2890717T (es)
ME (1) ME03799B (es)
MX (1) MX362514B (es)
NZ (2) NZ726258A (es)
PL (1) PL2890717T3 (es)
PT (1) PT2890717T (es)
RS (1) RS60217B1 (es)
RU (1) RU2668824C2 (es)
SG (2) SG10201804260QA (es)
SI (1) SI2890717T1 (es)
WO (1) WO2014036495A2 (es)
ZA (1) ZA201707245B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
TR201802659T4 (tr) 2011-04-01 2018-03-21 Immunogen Inc Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler.
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
WO2014205342A2 (en) * 2013-06-20 2014-12-24 Morphotek, Inc. Methods for treatment of ovarian cancer
CA2921975C (en) 2013-08-30 2024-02-13 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
PT3055332T (pt) * 2013-10-08 2019-12-09 Immunogen Inc Regimes de dosagem de imunoconjugados anti-folr1
WO2015149018A1 (en) * 2014-03-28 2015-10-01 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
US20170247449A1 (en) * 2014-06-06 2017-08-31 Kyowa Hakko Kirin Co., Ltd Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism
UA122676C2 (uk) * 2014-11-20 2020-12-28 Ф. Хоффманн-Ля Рош Аг Біспецифічна антигензв'язувальна молекула проти folr1 і cd3, що активує t-клітини
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
CN105548059B (zh) * 2016-01-29 2018-08-24 福建医科大学 叶酸-牛血清白蛋白-铂铋纳米复合材料
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN108982430B (zh) * 2017-05-31 2020-09-29 北京大学 标记细菌菌群样品的试剂盒、方法及应用
WO2019050935A1 (en) * 2017-09-05 2019-03-14 Immunogen, Inc. METHODS OF DETECTING FOLATE RECEPTOR 1 IN A SAMPLE FROM A PATIENT
KR20200132900A (ko) * 2018-03-13 2020-11-25 페인스 테라퓨틱스 인코포레이티드 항-폴레이트 수용체 1 항체 및 이의 용도
CN113728007A (zh) * 2019-04-12 2021-11-30 东莞凡恩世生物医药有限公司 人源化抗叶酸受体1嵌合抗原受体及其用途
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CN114163520B (zh) * 2021-11-23 2024-01-30 南京京达生物技术有限公司 一种血源性人IgM抗体纯化介质制备方法
CN117700557A (zh) * 2024-02-05 2024-03-15 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
EP0544809B1 (en) 1990-08-24 1998-12-16 Ixsys, Inc. Methods of synthesizing oligonucleotides with random codons
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2098824A1 (en) 1990-12-20 1992-06-21 William D. Huse Optimization of binding proteins
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
DK1133565T3 (da) 1999-07-02 2011-01-24 Morphosys Ag Generering af specifikke bindingspartnere til (poly)peptider, som der kodes for af genomiske DNA-fragmenter eller EST'er
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
US7033594B2 (en) 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002087424A2 (en) 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1486566A4 (en) 2002-03-01 2005-10-12 Japan Enviro Chemicals Ltd FOR BINDING TO FEMALE SEXUAL HORMONES, PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
US7531522B2 (en) 2002-04-22 2009-05-12 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
KR101441358B1 (ko) 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR20060030066A (ko) 2003-07-02 2006-04-07 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
WO2005054469A1 (en) 2003-12-05 2005-06-16 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
EP2316857A1 (en) * 2004-02-12 2011-05-04 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
EP1747462A2 (en) 2004-04-27 2007-01-31 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
EP1685161A1 (en) 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
CA2584859C (en) 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
US20070294782A1 (en) 2004-12-21 2007-12-20 Mark Abad Transgenic plants with enhanced agronomic traits
AP2007004034A0 (en) 2004-12-31 2007-06-30 Genentech Inc Polypeptides sthat bind br3 and uses thereof
EP1850866A4 (en) 2005-01-27 2009-07-08 Univ California MONOCLONAL THERAPEUTIC ANTIBODIES FOR THE NEUTRALIZATION OF BOTULIN NEUROTOXINES
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
RU2007139912A (ru) 2005-03-30 2009-05-10 Пердью Рисерч Фаундейшн (Us) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
JP2009521206A (ja) * 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
US7786266B2 (en) 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
AU2006250888A1 (en) 2005-05-24 2006-11-30 Avesthagen Limited A method for the production of a monoclonal antibody to CD20 for the treatment of B-cell lymphoma
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
WO2007022416A2 (en) 2005-08-18 2007-02-22 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
SG170749A1 (en) 2005-12-20 2011-05-30 Sbi Biotech Co Ltd Anti-ilt7 antibody
WO2007143561A1 (en) 2006-06-01 2007-12-13 Mayo Foundation For Medical Education And Research Immunity to folate receptors
WO2007147265A1 (en) 2006-06-23 2007-12-27 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US20090182955A1 (en) 2006-09-08 2009-07-16 Rao Cherukuri Application configuration across client devices of a local system
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
EP2103628A4 (en) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
WO2008076487A2 (en) 2006-12-20 2008-06-26 Verenium Corporation Antibodies and methods for making and using them
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2609934A1 (en) 2007-02-16 2013-07-03 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN101139613B (zh) 2007-08-01 2011-06-08 姜荣锡 抗肿瘤二元多肽及其应用与制备方法
JP5660900B2 (ja) 2007-12-21 2015-01-28 ノバルティス アーゲー 有機化合物
CA2711557A1 (en) 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
RU2568976C2 (ru) 2008-04-21 2015-11-20 Свапсол Корп. Преобразование сероводорода в водород
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
CN104258413A (zh) 2008-04-30 2015-01-07 伊缪诺金公司 有效的偶联物和亲水性连接体
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
NZ592255A (en) 2008-09-17 2013-07-26 Endocyte Inc Folate receptor binding conjugates of antifolates
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CN101440130B (zh) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
JP5923035B2 (ja) 2009-03-24 2016-05-24 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
WO2011100398A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
BR112013009275A2 (pt) * 2010-10-20 2017-06-20 Morphotek Inc glicoformas de anticorpo alfa de receptor anti-folato
EP2635304B1 (en) * 2010-11-05 2017-03-08 Morphotek, Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
EP2691155B1 (en) 2011-03-29 2018-11-14 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
MX2013011201A (es) 2011-03-29 2013-12-16 Immunogen Inc Proceso para la elaboracion de conjugados de mejor homogeneidad.
TR201802659T4 (tr) 2011-04-01 2018-03-21 Immunogen Inc Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler.
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
PL2731972T3 (pl) 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
EP2930240B1 (en) 2012-12-07 2018-08-01 Kyowa Hakko Kirin Co., Ltd. Anti-folr1 antibody
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
CA2911499A1 (en) 2013-05-14 2014-11-20 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
CA2921975C (en) 2013-08-30 2024-02-13 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
PT3055332T (pt) 2013-10-08 2019-12-09 Immunogen Inc Regimes de dosagem de imunoconjugados anti-folr1
WO2015149018A1 (en) 2014-03-28 2015-10-01 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
JP2022022420A (ja) 2022-02-03
NZ726258A (en) 2019-07-26
AU2020204602A1 (en) 2020-07-30
CN110294805A (zh) 2019-10-01
CA2883222C (en) 2021-12-14
CA2883222A1 (en) 2014-03-06
ME03799B (me) 2021-04-20
CN104755498B (zh) 2019-06-18
AU2013308497A1 (en) 2015-02-26
RS60217B1 (sr) 2020-06-30
KR20240005129A (ko) 2024-01-11
IL264770B (en) 2021-02-28
IL237087B (en) 2019-05-30
US10180432B2 (en) 2019-01-15
HRP20200482T1 (hr) 2020-06-26
WO2014036495A4 (en) 2014-05-08
US9200073B2 (en) 2015-12-01
JP2018042573A (ja) 2018-03-22
AU2013308497B2 (en) 2018-06-28
CN110294805B (zh) 2023-08-15
RU2668824C2 (ru) 2018-10-02
KR20210145850A (ko) 2021-12-02
JP2015533788A (ja) 2015-11-26
JP2020018325A (ja) 2020-02-06
HUE049693T2 (hu) 2020-10-28
US20160146824A1 (en) 2016-05-26
IL237087A0 (en) 2015-03-31
JP2023111942A (ja) 2023-08-10
US20190227073A1 (en) 2019-07-25
ES2788151T3 (es) 2020-10-20
JP7289346B2 (ja) 2023-06-09
HK1210188A1 (en) 2016-04-15
CN104755498A (zh) 2015-07-01
NZ630433A (en) 2017-10-27
KR20150046316A (ko) 2015-04-29
EP2890717B1 (en) 2020-03-04
US9702881B2 (en) 2017-07-11
IL280634A (en) 2021-03-25
EP3712175A1 (en) 2020-09-23
BR112015004229B1 (pt) 2023-02-07
AU2018203934B2 (en) 2020-05-07
IL280634B2 (en) 2023-06-01
EP2890717A4 (en) 2016-08-03
IL299620A (en) 2023-03-01
JP6293147B2 (ja) 2018-03-14
US10613093B2 (en) 2020-04-07
JP6480558B2 (ja) 2019-03-13
WO2014036495A3 (en) 2014-04-10
ZA201707245B (en) 2019-05-29
RU2018133493A (ru) 2020-03-24
CA3137438A1 (en) 2014-03-06
SG10201804260QA (en) 2018-07-30
AU2018203934A1 (en) 2018-06-21
US20200333347A1 (en) 2020-10-22
WO2014036495A2 (en) 2014-03-06
SG11201500938XA (en) 2015-04-29
US20230213524A1 (en) 2023-07-06
KR20200079565A (ko) 2020-07-03
US20180003715A1 (en) 2018-01-04
PL2890717T3 (pl) 2020-08-10
LT2890717T (lt) 2020-06-10
EP2890717A2 (en) 2015-07-08
AU2023210668A1 (en) 2023-08-31
RU2015104579A (ru) 2016-10-20
PT2890717T (pt) 2020-04-22
DK2890717T3 (da) 2020-05-11
SI2890717T1 (sl) 2020-07-31
BR112015004229A2 (pt) 2017-08-08
MX2015002605A (es) 2015-06-10
KR102617499B1 (ko) 2023-12-22
JP2018088942A (ja) 2018-06-14
CY1122907T1 (el) 2021-10-29
US20140099332A1 (en) 2014-04-10
AU2020204602B2 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
CY1124428T1 (el) Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
EP3865135A3 (en) Neuroactive steroids for use in therapy
MX2017015260A (es) Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
MX2014013995A (es) Metodos para tratar o predecir riesgo de un evento de taquiarritmia ventricular.
MX2019015155A (es) Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
GEP201706737B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
WO2013071012A3 (en) Personalized strategic cancer treatment
WO2012145535A3 (en) Animal model of human cancer and methods of use
MX370570B (es) Marcador para trastornos de la esfingomielinasa acida y sus usos.
MX2019008005A (es) Metodos y composiciones para diagnosticar preeclampsia.
WO2016168359A8 (en) Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
GB201121914D0 (en) Method for patient selection
TN2012000590A1 (en) Apparatus, method and computer-readable storage medium for evaluating a physiological condition of a patient
AU2013231230A8 (en) Method for selecting or identifying a subject for V1B antagonist therapy
MX2021000215A (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
EA201001297A1 (ru) Способ диагностики меланомы человека на основании определения уровня экспрессии гена phf10, диагностический набор
UA93325U (uk) Спосіб діагностики зрощеного перелому
UA93315U (uk) Спосіб діагностики незрощеного перелому
UA93314U (uk) Спосіб діагностики незрощеного перелому
UA93328U (uk) Спосіб прогнозування незрощеного перелому
UA104420U (uk) Спосіб прогнозування зрощення перелому

Legal Events

Date Code Title Description
FG Grant or registration